Atopic Dermatitis (AD) is a chronic inflammatory skin disease characterized by Th1/Th2 lymphocyte imbalance. GemPharmatech uses Oxazolone (OXA) to induce atopic dermatitis in mice. This model can be used to test the efficacy of AD drugs.

Modeling strategy

Validation data

Compared with G2 (the OXA modeling group), the skin thickness of mouse back (upper left) and ear (upper right) was significantly decreased after dexamethasone administration, so were the clinical score (lower left), and the serum IgE levels (lower right). The results demonstrate that OXA-induced atopic dermatitis model can be used for efficacy testing. DXMS: dexamethasone

Inflammatory cells (black arrow), epidermal thickening (red arrow), hypokeratosis (green arrow), hyperkeratosis (blue arrow), keratinized pearl (yellow arrow). Bar=500 µm in the upper row. Bar=200 µm in the lower row. DXMS: dexamethasone